Latest Deals
Credit: Valeriya Zankovych/Shutterstock.com
AbbVie diversifies oncology portfolio with $10.1 bn ImmunoGen acquisition
In a bid to expand its oncology pipeline AbbVie has announced it will acquire ImmunoGen under a definitive agreement. The proposed $10.1bn acquisition will see AbbVie purchase ImmunoGen’s outstanding shares at $31.26 per share. The acquisition is expected to be completed in mid-2024. On an investor call fAbbVie’s executive vice president and chief financial officer Scott Reents, said the funding of the transaction will be driven by a combination of cash and debt.
Roche to acquire Carmot Therapeutics for $2.7bn
Roche has signed an agreement for the acquisition of US-based company Carmot Therapeutics in a $2.7bn cash deal. Carmot and its employees will become part of the pharmaceuticals segment of Roche. The merger is expected to conclude in the first quarter of 2024. Carmot’s stakeholders are eligible to receive $400m in milestone payments on meeting specified goals.
Sanofi signs $140m small molecule discovery deal with Aqemia
Sanofi has entered a multi-year research collaboration deal with French pharmatech Aqemia to develop small molecule drug candidates for several different undisclosed therapeutic areas. qemia will design the drug molecules using its artificial intelligence (AI) platform, using physics-based calculations that generate data to accelerate drug discovery. Sanofi will take hold of wet lab research, development, and commercialisation.
AbbVie to acquire Cerevel Therapeutics for $8.7bn
AbbVie has signed a definitive agreement to acquire Cerevel Therapeutics in an $8.7bn cash deal. AbbVie will gain access to Cerevel’s neuroscience pipeline of multiple clinical-stage and preclinical candidates for conditions including schizophrenia and Parkinson’s disease. The deal is part of AbbVie’s strategy of bolstering its neuroscience portfolio, adding assets to enhance standards of care in psychiatric and neurological disorders.
